Aurora Investment Managers LLC. Acquires 192 Shares of Illumina, Inc. $ILMN

Aurora Investment Managers LLC. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,258 shares of the life sciences company’s stock after buying an additional 192 shares during the quarter. Aurora Investment Managers LLC.’s holdings in Illumina were worth $1,456,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Diversified Trust Co bought a new position in shares of Illumina during the first quarter valued at $355,000. Bourgeon Capital Management LLC lifted its holdings in Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock valued at $13,538,000 after purchasing an additional 61,468 shares during the last quarter. GC Wealth Management RIA LLC bought a new position in Illumina during the 2nd quarter valued at about $2,289,000. State of Alaska Department of Revenue raised its stake in shares of Illumina by 2.5% in the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock valued at $1,469,000 after acquiring an additional 445 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in shares of Illumina by 171.2% in the first quarter. Acadian Asset Management LLC now owns 32,921 shares of the life sciences company’s stock valued at $2,608,000 after acquiring an additional 20,784 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 1.1%

ILMN opened at $97.78 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market cap of $15.03 billion, a price-to-earnings ratio of 12.38, a price-to-earnings-growth ratio of 2.33 and a beta of 1.40. The firm has a 50 day simple moving average of $98.47 and a 200 day simple moving average of $90.11. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their target price on shares of Illumina from $99.00 to $105.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research report on Tuesday, September 2nd. Daiwa Capital Markets cut Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target for the company. in a report on Tuesday, August 12th. Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a report on Friday, July 11th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research note on Wednesday. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $123.56.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.